Skip to main content
Top
Published in: AIDS and Behavior 2/2020

01-02-2020 | Human Immunodeficiency Virus | Original Paper

Evaluating Measures of Pre-ART Adherence Readiness Through Associations with ART Adherence in the Early Months of Treatment

Authors: Gulrez Shah Azhar, Stefan Schneider, Risa Hoffman, Kyle Gordon, Daniel Ramirez, Glenn Wagner

Published in: AIDS and Behavior | Issue 2/2020

Login to get access

Abstract

Determining a patient’s readiness to adhere well prior to the start of ART provides an opportunity to address adherence barriers before poor pill taking habits form, and ultimately improve clinical outcomes and resource utilization. Three methods of measuring adherence readiness and their comparative utility in predicting early ART adherence were examined in a sample of 176 patients preparing to start ART. Data were analyzed data from a randomized controlled trial of a cognitive-behavioral adherence intervention. Three measures of pre-ART adherence readiness (provider estimate, 1 week vitamin practice trials, and self-report [HIV Medication Readiness Scale; Transtheoretical Stages of Change item (TSOC)] were examined in association with measures of (1) ART initiation, (2) ART retention, (3) mean electronic dose-taking adherence, and (4) achievement of optimal (85+ % dose-taking) adherence, over the first 3 months of ART. Of the 176 patients, 166 (94.3%) started ART; 124 (74.7% of those who started ART; 70.5% of whole sample) completed the first 3 months of ART. Among the 124 still on ART at month 3, mean dose-taking adherence was 79.3%, and 62 (35.2% of whole sample) achieved optimal adherence. The provider estimate was the only readiness measure significantly associated with each of the four measures of early ART adherence, and it had the highest concordance statistics (71% PPV and 62.3% NPV) with optimal early ART adherence. Practice trial adherence was only associated with ART initiation and retention. Dose-taking adherence over 3 months was significantly correlated with the provider estimate and the two self-reports. Each method of early treatment adherence has its own utility, but the provider estimate had the best overall performance in predicting early ART adherence.
Literature
1.
go back to reference Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45(3):372–9.CrossRef Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45(3):372–9.CrossRef
2.
go back to reference Pasternak AO, de Bruin M, Jurriaans S, Bakker M, Berkhout B, Prins JM, et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis. 2012;206(9):1443–52.CrossRef Pasternak AO, de Bruin M, Jurriaans S, Bakker M, Berkhout B, Prins JM, et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis. 2012;206(9):1443–52.CrossRef
3.
go back to reference Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26(5):435–42.CrossRef Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26(5):435–42.CrossRef
4.
go back to reference Bouton ME. A learning theory perspective on lapse, relapse, and the maintenance of behavior change. Health Psychol. 2000;19(1S):57.CrossRef Bouton ME. A learning theory perspective on lapse, relapse, and the maintenance of behavior change. Health Psychol. 2000;19(1S):57.CrossRef
6.
go back to reference Sylvain H, Delmas P. Readiness in HIV treatment adherence: a matter of confidence. An exploratory study. Open AIDS J. 2011;5:119.CrossRef Sylvain H, Delmas P. Readiness in HIV treatment adherence: a matter of confidence. An exploratory study. Open AIDS J. 2011;5:119.CrossRef
7.
go back to reference Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL. Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS. 2002;16(13):1835–7.CrossRef Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL. Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS. 2002;16(13):1835–7.CrossRef
8.
go back to reference Miller LG, Liu H, Hays RD, Golin CE, Beck CK, Asch SM, et al. How well do clinicians estimate patients’ adherence to combination antiretroviral therapy? J Gen Intern Med. 2002;17(1):1–11.CrossRef Miller LG, Liu H, Hays RD, Golin CE, Beck CK, Asch SM, et al. How well do clinicians estimate patients’ adherence to combination antiretroviral therapy? J Gen Intern Med. 2002;17(1):1–11.CrossRef
9.
go back to reference Wagner G. Placebo practice trials: the best predictor of adherence readiness for HAART among drug users? HIV Clin Trials. 2003;4(4):269–81.CrossRef Wagner G. Placebo practice trials: the best predictor of adherence readiness for HAART among drug users? HIV Clin Trials. 2003;4(4):269–81.CrossRef
10.
11.
go back to reference Willey C, Redding C, Stafford J, Garfield F, Geletko S, Flanigan T, et al. Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. Clin Ther. 2000;22(7):858–71.CrossRef Willey C, Redding C, Stafford J, Garfield F, Geletko S, Flanigan T, et al. Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. Clin Ther. 2000;22(7):858–71.CrossRef
12.
go back to reference Konkle-Parker DJ. A motivational intervention to improve adherence to treatment of chronic disease. J Am Acad Nurse Pract. 2001;13(2):61–8.CrossRef Konkle-Parker DJ. A motivational intervention to improve adherence to treatment of chronic disease. J Am Acad Nurse Pract. 2001;13(2):61–8.CrossRef
13.
go back to reference Grimes RM, Grimes DE. Readiness, trust, and adherence: a clinical perspective. J Int Assoc Provid AIDS Care (JIAPAC). 2013;12(3):185–94.CrossRef Grimes RM, Grimes DE. Readiness, trust, and adherence: a clinical perspective. J Int Assoc Provid AIDS Care (JIAPAC). 2013;12(3):185–94.CrossRef
14.
go back to reference Wagner GJ, Linnemayr S, Ghosh-Dastidar B, Currier JS, Hoffman R, Schneider S. Supporting treatment adherence readiness through training (START) for patients with HIV on antiretroviral therapy: study protocol for a randomized controlled trial. Trials. 2016;17(1):162.CrossRef Wagner GJ, Linnemayr S, Ghosh-Dastidar B, Currier JS, Hoffman R, Schneider S. Supporting treatment adherence readiness through training (START) for patients with HIV on antiretroviral therapy: study protocol for a randomized controlled trial. Trials. 2016;17(1):162.CrossRef
15.
go back to reference Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.CrossRef Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.CrossRef
16.
go back to reference Balfour L, Tasca GA, Kowal J, Corace K, Cooper CL, Angel JB, et al. Development and validation of the HIV Medication Readiness Scale. Assessment. 2007;14(4):408–16.CrossRef Balfour L, Tasca GA, Kowal J, Corace K, Cooper CL, Angel JB, et al. Development and validation of the HIV Medication Readiness Scale. Assessment. 2007;14(4):408–16.CrossRef
17.
go back to reference Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12(1):38–48.CrossRef Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12(1):38–48.CrossRef
18.
go back to reference Highstein GR, Willey C, Mundy LM. Development of stage of readiness and decisional balance instruments: tools to enhance clinical decision-making for adherence to antiretroviral therapy. AIDS Behav. 2006;10:563–73.CrossRef Highstein GR, Willey C, Mundy LM. Development of stage of readiness and decisional balance instruments: tools to enhance clinical decision-making for adherence to antiretroviral therapy. AIDS Behav. 2006;10:563–73.CrossRef
Metadata
Title
Evaluating Measures of Pre-ART Adherence Readiness Through Associations with ART Adherence in the Early Months of Treatment
Authors
Gulrez Shah Azhar
Stefan Schneider
Risa Hoffman
Kyle Gordon
Daniel Ramirez
Glenn Wagner
Publication date
01-02-2020
Publisher
Springer US
Published in
AIDS and Behavior / Issue 2/2020
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02708-0

Other articles of this Issue 2/2020

AIDS and Behavior 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.